糖尿病胃衰竭的常见病理生理机制和治疗方法
Yu-Xin Zhang1, Yan-Jiao Zhang1, Min Li1
1Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Journal of neurogastroenterology and motility
|April 5, 2024
概括
糖尿病性胃衰竭 (DGP) 是一种糖尿病并发症,导致胃排空延迟和消化系统问题. 本综述探讨了DGP机制和 prokinetic 治疗方法,以指导未来的研究和治疗.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病性胃衰竭 (DGP) 是糖尿病的一个普遍并发症.
- 它的特点是胃排空延迟而没有机械阻塞,导致恶心和吐等症状.
- DGP显著影响患者的生活质量和生产力.
研究的目的:
- 审查最近关于DGP和胃肠机动性障碍背后的机制的文献.
- 检查胃肠道运动障碍的发动性治疗方法的发展.
- 确定DGP的未来研究方向和治疗策略.
主要方法:
- 对DGP最近研究的文献综述.
- 对胃肠道动力学和运动障碍研究的分析.
- 对 prokinetic 治疗开发的评估.
主要成果:
- DGP与Cajal功能障碍的间歇细胞和神经内分泌异常等因素有关.
- 胃肠道运动障碍是复杂的和多因素的.
- 促动疗法是管理DGP的持续发展领域.
结论:
- 了解DGP机制对于有效治疗至关重要.
- 进一步研究 prokinetic 疗法是有必要的.
- 需要综合策略来解决DGP并改善患者的治疗结果.
相关概念视频
Pathophysiology of Diabetes
926
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
926
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
313
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
313
Gastrointestinal Motility Disorders
349
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
349
Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
530
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
530
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)

